Acute myeloid leukemia（AML）is the most common type of acute leukemia in adults. The“3+7”regimen composed of anthracyclines and cytarabine has been established as the standard induction regimen for AML patients since the 1970 s. Since then， on going clinical studies have focused on optimizing the first-line induction regimen and evaluating whether new regimens have more advantages in terms of efficacy and safety compared to the standard induction regimen. This article mainly describes the progress of first-line induction therapy regimens for AML，and the research of related molecular targeted drugs，so as to provide reference for clinical treatment.